We advised GSK on the transaction 

Davis Polk advised GSK plc in connection with its multi-target strategic alliance with Vesalius Therapeutics, Inc. Vesalius will leverage its platform to identify novel intervention points in Parkinson’s disease and one additional indication in neurodegeneration and GSK will have the option to advance programs against those novel intervention points. GSK will also gain worldwide development and commercial rights to a preclinical small molecule program with an initial focus in Parkinson’s disease from Vesalius. GSK will control all development and commercialization. Vesalius will receive $80 million in upfront and equity payments, and is eligible to receive potential preclinical, development and commercial milestone payments of up to $570 million along with tiered royalties for the preclinical small molecule program. In addition, Vesalius is eligible to receive potential preclinical, development and commercial milestone payments and tiered royalties for each of the novel intervention points that result from the multitarget deal.

GSK is a global biopharmaceutical company with a purpose to unite science, technology and talent to get ahead of disease together.

Vesalius, a company founded by Flagship Pioneering, is pioneering a revolutionary platform to generate breakthrough treatments for common diseases. Its platform uses large-scale human genetics, genomics, stem cell studies and artificial intelligence to uncover causal biology and identify optimal intervention points for new therapies.

The Davis Polk IP and commercial transactions team included partner David R. Bauer, counsel Samantha Lefland and associate Emma Willems. Partners William J. Chudd and Daniel Brass and associate Rachel Schlosser provided corporate advice. The antitrust and competition team included partner Jesse Solomon and counsel Mary K. Marks and Matthew Yeowart. Partner William A. Curran provided tax advice. Members of the Davis Polk team are based in the New York, Washington DC and London offices. 

Copy link to share post